{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:03:09Z","timestamp":1765605789574,"version":"3.48.0"},"reference-count":30,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773065"],"award-info":[{"award-number":["81773065"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY21H160023"],"award-info":[{"award-number":["LY21H160023"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,6,19]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      is the most well-known risk factor for gastric cancer. Antibiotic resistance is the main reason for the failure of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication, and understanding the antibiotic resistance before treatment may be the main determinant of successful eradication of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      . This study aims to evaluate the efficacy and safety of quadruple therapy based on faecal molecular antimicrobial susceptibility tests for the first-line eradication of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This is a single-centre, single-blind, randomised controlled trial, enrolling 855 patients with\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection. Patients are randomised to three groups for a 14-day treatment: group A: amoxicillin- and clarithromycin-based bismuth-containing quadruple therapy (BQT) (rabeprazole 10\u2009mg, amoxicillin 1\u2009g, clarithromycin 500\u2009mg and colloidal bismuth 200\u2009mg two times per day); group B: clarithromycin medication history-based BQT (rabeprazole 10\u2009mg, amoxicillin 1\u2009g, furazolidone 100\u2009mg (with clarithromycin medication history)\/clarithromycin 500\u2009mg (without clarithromycin medication history) and colloidal bismuth 200\u2009mg two times per day); group C: antimicrobial susceptibility test-based BQT (rabeprazole 10\u2009mg, amoxicillin 1\u2009g, clarithromycin 500\u2009mg (clarithromycin-sensitive)\/furazolidone 100\u2009mg (clarithromycin resistant) and colloidal bismuth 200\u2009mg two times per day). The primary end point is the eradication rate. The secondary end points are the incidence of adverse events and compliance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the Ethics Committee of Second Affiliated Hospital, School of Medicine, Zhejiang University (Number 20230103). The results will be published in the appropriate peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05718609\">NCT05718609<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-072670","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:36:47Z","timestamp":1689946607000},"page":"e072670","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for\n                    <i>Helicobacter pylori<\/i>\n                    infection: a protocol of a single-centre, single-blind, randomised clinical trial in China"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05718609","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yaoyi","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oulan","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochun","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Institute (Key Laboratory for Cancer Intervention and Prevention, China National Ministry of Education, Zhejiang Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Zhejiang University Cancer Center, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0324-978X","authenticated-orcid":false,"given":"Jun","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2025121222004221000_13.7.e072670.1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"},{"key":"2025121222004221000_13.7.e072670.2","doi-asserted-by":"crossref","unstructured":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2019. doi:10.1016\/S2214-109X(19)30488-7","DOI":"10.1016\/S2214-109X(19)30488-7"},{"key":"2025121222004221000_13.7.e072670.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.05.023"},{"key":"2025121222004221000_13.7.e072670.4","unstructured":"The sixth national guidelines for the treatment of Helicobacter Pylori infection 2022, quick review. Yixuejie 2022. Available: https:\/\/www.yxj.org.cn\/detailPage?articleId=323906"},{"key":"2025121222004221000_13.7.e072670.5","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12597","article-title":"Guidelines for the management of Helicobacter Pylori infection in Japan: 2016 revised edition","volume":"24","author":"Kato","year":"2019","journal-title":"Helicobacter"},{"key":"2025121222004221000_13.7.e072670.6","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese national consensus report on the management of Helicobacter Pylori infection","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"2025121222004221000_13.7.e072670.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062096","article-title":"Short-term outcomes and intermediate-term follow-up of Helicobacter Pylori infection treatment for naive patients: a retrospective observational study","volume":"12","author":"Wang","year":"2022","journal-title":"BMJ Open"},{"key":"2025121222004221000_13.7.e072670.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.007"},{"key":"2025121222004221000_13.7.e072670.9","first-page":"5027","article-title":"A retrospective study of the antibiotic-resistant phenotypes and Genotypes of Helicobacter Pylori strains in China","volume":"11","author":"Zhong","year":"2021","journal-title":"Am J Cancer Res"},{"key":"2025121222004221000_13.7.e072670.10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","article-title":"Primary antibiotic resistance in Helicobacter Pylori in the Asia-Pacific region: a systematic review and meta-analysis","volume":"2","author":"Kuo","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121222004221000_13.7.e072670.11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/apt.15273","article-title":"Randomised controlled trial: susceptibility-guided therapy versus Empiric bismuth quadruple therapy for first-line Helicobacter Pylori treatment","volume":"49","author":"Chen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121222004221000_13.7.e072670.12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00740-07"},{"key":"2025121222004221000_13.7.e072670.13","unstructured":"Sixth national consensus report on Helicobacter Pylori infection management (part of non-eradication treatment). Zhonghua Xiao Hua Zazhi 2022;42."},{"key":"2025121222004221000_13.7.e072670.14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.2.283"},{"key":"2025121222004221000_13.7.e072670.15","doi-asserted-by":"publisher","DOI":"10.1080\/00313020120105624"},{"key":"2025121222004221000_13.7.e072670.16","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01787-19","article-title":"Diagnostic accuracy of a noninvasive test for detection of Helicobacter Pylori and resistance to Clarithromycin in stool by the Amplidiag H. Pylori+Clarir real-time PCR assay","volume":"58","author":"Pichon","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2025121222004221000_13.7.e072670.17","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12515","article-title":"Diagnosis of Helicobacter Pylori infection","volume":"23 Suppl 1","author":"Skrebinska","year":"2018","journal-title":"Helicobacter"},{"key":"2025121222004221000_13.7.e072670.18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17843286.2019.1685741","article-title":"Molecular detection of Helicobacter Pylori and Clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA(R)GENE Helicobacter Pylori assay","volume":"76","author":"Van den Poel","year":"2021","journal-title":"Acta Clin Belg"},{"key":"2025121222004221000_13.7.e072670.19","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.03040-20","article-title":"Clinical evaluation of a real-time PCR assay for simultaneous detection of Helicobacter Pylori and Genotypic markers of Clarithromycin resistance directly from stool","volume":"59","author":"Marrero Rolon","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2025121222004221000_13.7.e072670.20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02530-16","article-title":"Phenotypic and molecular antimicrobial susceptibility of Helicobacter Pylori","volume":"61","author":"Chen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121222004221000_13.7.e072670.21","first-page":"155","article-title":"Eradication therapy for Helicobacter Pylori infection guided by drug sensitive trials","volume":"37","author":"Zhou","year":"2017","journal-title":"Zhonghua Xiao Hua Zazhi"},{"key":"2025121222004221000_13.7.e072670.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22557-7","article-title":"Primary and secondary Clarithromycin resistance in Helicobacter Pylori and mathematical modeling of the role of macrolides","volume":"12","author":"Kocsm\u00e1r","year":"2021","journal-title":"Nat Commun"},{"key":"2025121222004221000_13.7.e072670.23","doi-asserted-by":"publisher","DOI":"10.1159\/000076471"},{"key":"2025121222004221000_13.7.e072670.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037375","article-title":"Safety of Furazolidone-containing regimen in Helicobacter Pylori infection: a systematic review and meta-analysis","volume":"10","author":"Ji","year":"2020","journal-title":"BMJ Open"},{"key":"2025121222004221000_13.7.e072670.25","unstructured":"List of classifications. n.d. Available: https:\/\/monographs.iarc.who.int\/list-of-classifications"},{"key":"2025121222004221000_13.7.e072670.26","unstructured":"Furazolidone, UPS. n.d. Available: https:\/\/dailymed.nlm.nih.gov\/ dailymed\/fda\/fdaDrugXsl.cfm?setid=056f4352-baaa-4f47-9fb3fc2bdde6b26e"},{"key":"2025121222004221000_13.7.e072670.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025121222004221000_13.7.e072670.28","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.3748\/wjg.v24.i40.4596","article-title":"Outcomes of Furazolidone- and Amoxicillin-based quadruple therapy for Helicobacter Pylori infection and predictors of failed eradication","volume":"24","author":"Zhang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2025121222004221000_13.7.e072670.29","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12940","article-title":"Quadruple therapy with Vonoprazan 20 mg daily as a first-line treatment for Helicobacter Pylori infection: A single-center, open-label, Noninferiority, randomized controlled trial","volume":"28","author":"Lu","year":"2023","journal-title":"Helicobacter"},{"key":"2025121222004221000_13.7.e072670.30","first-page":"75","article-title":"Amoxicillin-Clarithromycin-containing bismuth quadruple therapy for primary eradication of Helicobacter Pylori","volume":"41","author":"Guo","year":"2019","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-072670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:00:52Z","timestamp":1765605652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-072670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,21]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bmjopen-2023-072670"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-072670","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}